Go to the list of all blogs
Sergey Savastiouk's Avatar
published in Blogs
Nov 09, 2026
TickeronGET DAILY SIGNALS
Goosehead Insurance (GSHD) and the +30% Path to the $62 Analyst Target

Goosehead Insurance (GSHD) and the +30% Path to the $62 Analyst Target

Key Takeaways

  • The central target of $62 is the arithmetic mean of the most recent verifiable analyst price targets for GSHD, rounded from a calculated average near $62.
  • At a recent price near $47.60, reaching $62 would require roughly a 30% advance — a substantial, but not extreme, move.
  • The individual analyst targets span a wide range from about $42 to $80, signaling genuine disagreement about the company's growth and valuation outlook.
  • The strongest supporting factors are mid-teens revenue growth, an expanding franchise producer base, and an improving earnings trajectory projected into 2027.
  • The biggest risks are slowing growth momentum, margin pressure from higher investment spending, and concerns that generative AI could disrupt insurance distribution.
  • For more context on this stock, explore its Major News, Today's Price Move, Forecast, and Earnings pages.
  • You can also monitor evolving technical and AI-driven signals through Trending AI Robots.

Analyst Price Targets and the Consensus View

Goosehead Insurance, Inc. (GSHD), a personal-lines insurance distribution company, is covered by roughly a dozen sell-side firms. The most recent verifiable targets span approximately $42 to $80, with the arithmetic mean landing near $62 after rounding. This wide dispersion reflects a genuine split: several firms still carry Buy or Outperform ratings with targets in the mid-$60s to $80 range, while a larger group of Hold and Neutral ratings cluster in the high-$40s to low-$60s.

The most recent revisions have leaned downward. Piper Sandler downgraded the stock to Neutral and cut its target from $72 to $48 in early October 2026, citing concerns over revenue-growth guidance. Citizens JMP lowered its target from $100 to $80, and Keefe, Bruyette & Woods cut from $72 to $66, while J.P. Morgan trimmed to $60, Truist to $48, BMO Capital to $47, and Bank of America Securities maintained an Underperform/Sell stance at $42. The bull-and-bear split is driven by differing assumptions about how durable the company's premium and commission growth will remain, and whether its valuation can hold up as growth decelerates. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.

Current Market Position and the Path Toward the Target

With the stock recently trading near $47.60, reaching a $62 stock price target would require an advance of roughly 30%. That qualifies as a substantial move, not a marginal one. Goosehead's revenue is still growing — consensus estimates point to roughly $425 million in revenue for 2026, up about 16% — but the company has been reinvesting in its franchise and corporate distribution channels, which has pressured near-term margins and earnings. Wall Street currently models EPS (earnings per share) of about $2.10 for 2026, rising toward roughly $2.63 in 2027 as those investments mature. A move toward $62 would likely require the market to regain confidence that revenue growth can hold in the mid-teens while profitability re-accelerates, allowing the stock to command a higher forward multiple than it does today.

What Could Support a Move Toward the Target

Goosehead's core growth engine remains intact. The company continues to add franchise and corporate producers, and its book of policies generates recurring royalty and commission income as premiums renew. Renewal revenue tends to be sticky, which gives the business a degree of visibility that many high-growth financial names lack. If new-producer productivity improves and the elevated investment spending begins to pay off, earnings growth could accelerate into 2027 and justify a higher valuation. Analyst revisions have not been uniformly negative — Cantor Fitzgerald, UBS, and Citizens JMP have retained constructive ratings — and the stock's sharp de-rating in 2026 means even a modest re-rating, combined with higher earnings, could narrow the gap toward $62.

What Could Prevent the Target From Being Reached

The principal obstacle is the deterioration in sentiment and valuation that defined 2026. The shares have declined sharply from their earlier highs as revenue-growth momentum slowed, and management has guided more cautiously, prompting several firms to trim estimates and targets. A second, widely cited risk is the possibility that generative AI tools disintermediate traditional insurance distribution, pressuring Goosehead's agency-based model. Higher investment spending, softer renewal-commission retention, and margin compression all weigh on near-term EPS, and a stock trading at a forward multiple that already embeds meaningful growth can de-rate quickly if that growth disappoints. If AI-related concerns persist or producer-driven growth stalls, the low-$40s targets imply downside rather than a path to $62.

Technical Levels and Market Structure

The stock's steep 2026 decline has left it trading near the lower end of its recent range. The $42-to-$44 area, which corresponds to the lowest analyst targets and recent trading lows, represents the clearest downside support zone, while $50 marks a psychological level the shares have struggled to hold. On the upside, the high-$50s to low-$60s region aligns with the cluster of Hold-rated targets and would likely act as the first meaningful resistance on any recovery toward the $62 level.

Time Horizon and What Investors Should Monitor

Analyst price targets generally reflect a roughly 12-month research horizon, though individual firms apply their own assumptions. The next key catalyst is Goosehead's third-quarter earnings report, scheduled for November 9, 2026, where results and forward guidance will test the roughly $0.51 per-share consensus estimate. Beyond that, investors should watch producer-count growth, premium retention and renewal rates, any change to margin guidance, and the pace of analyst estimate revisions. Broader factors, including insurance pricing trends and the market's evolving view of AI disruption risk, will also shape whether the shares can close the roughly 30% gap to $62.

Incorporating AI Signals Into My Research

In my own analysis, I often turn to Tickeron’s AI Daily Buy/Sell Signals to get a systematic read on names like GSHD. The tool uses artificial intelligence to continuously monitor thousands of stocks and ETFs, generating Buy, Sell, or Hold signals based on changing market conditions, technical behavior, and AI-driven analysis. It helps me discover new opportunities, keep an eye on existing positions, and spot shifting trends more efficiently than manual screening alone. Exploring these signals alongside traditional research adds a useful, data-driven layer to the decision-making process.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Related Ticker: GSHD

Contributor

Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.


GSHD's MACD Histogram just turned positive

The Moving Average Convergence Divergence (MACD) for GSHD turned positive on October 08, 2026. Looking at past instances where GSHD's MACD turned positive, the stock continued to rise in 36 of 44 cases over the following month. The odds of a continued upward trend are 82%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on October 20, 2026. You may want to consider a long position or call options on GSHD as a result. In 66 of 86 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 77%.

GSHD moved above its 50-day moving average on November 04, 2026 date and that indicates a change from a downward trend to an upward trend.

The 10-day moving average for GSHD crossed bullishly above the 50-day moving average on November 09, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 10 of 13 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 77%.

Following a +8.90% 3-day Advance, the price is estimated to grow further. Considering data from situations where GSHD advanced for three days, in 228 of 302 cases, the price rose further within the following month. The odds of a continued upward trend are 75%.

The Aroon Indicator entered an Uptrend today. In 138 of 201 cases where GSHD Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 69%.

Bearish Trend Analysis

The 10-day RSI Indicator for GSHD moved out of overbought territory on November 06, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 31 similar instances where the indicator moved out of overbought territory. In 25 of the 31 cases, the stock moved lower in the following days. This puts the odds of a move lower at 81%.

The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 4 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where GSHD declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 76%.

GSHD broke above its upper Bollinger Band on November 02, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Fundamental Analysis (Ratings)

The Tickeron SMR rating for this company is 19 (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Seasonality Score of 23 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron Price Growth Rating for this company is 41 (best 1 - 100 worst), indicating steady price growth. GSHD’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron PE Growth Rating for this company is 83 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Valuation Rating of 96 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: GSHD's P/B Ratio (-11.764) is very low in comparison to the industry average of (2.681). P/E Ratio (38.846) is within average values for comparable stocks, (19.012). GSHD's Projected Growth (PEG Ratio) (76.820) is very high in comparison to the industry average of (8.322). GSHD's Dividend Yield (0.426) is considerably higher than the industry average of (0.039). P/S Ratio (5.184) is also within normal values, averaging (2.968).

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. GSHD’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 85, placing this stock worse than average.

Notable companies

The most notable companies in this group are eHealth (NASDAQ:EHTH).

Industry description

Insurance brokers sell, solicit, or negotiate insurance for compensation. General insurance brokers mostly cater to insurances on car, house etc. (versus life). Brokers are also often instrumental in helping small employers find health insurance, particularly in more competitive markets. Additionally, brokers may also provide risk assessments, insurance consulting services, insurance-related regulatory and legislative update services. Some of the major names in this industry include Marsh & McLennan Companies, Inc., Aon plc and Verisk Analytics Inc.

Market Cap

The average market capitalization across the Insurance Brokers/Services Industry is 15.27B. The market cap for tickers in the group ranges from 3.03K to 97.74B. MRSH holds the highest valuation in this group at 97.74B. The lowest valued company is CUII at 3.03K.

High and low price notable news

The average weekly price growth across all stocks in the Insurance Brokers/Services Industry was -1%. For the same Industry, the average monthly price growth was 10%, and the average quarterly price growth was 19%. TREE experienced the highest price growth at 35%, while LIFE experienced the biggest fall at -16%.

Volume

The average weekly volume growth across all stocks in the Insurance Brokers/Services Industry was -16%. For the same stocks of the Industry, the average monthly volume growth was 6% and the average quarterly volume growth was -32%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 59
P/E Growth Rating: 69
Price Growth Rating: 48
SMR Rating: 70
Profit Risk Rating: 84
Seasonality Score: 5 (-100 ... +100)
AI Screener 3
View a ticker or compare two or three
Interact to see
Advertisement
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

a provider of insurance agency services

Industry InsuranceBrokersServices

Industry
Insurance Brokers Or Services
Address
1500 Solana Boulevard
Phone
+1 214 838-5500
Employees
1600
Web
https://ir.gooseheadinsurance.com
Interact to see
Advertisement
AtlasClear Holdings (ATCH) shares fell roughly 25.5% over the last 30 days, declining from $0.1881 on October 2 to $0.1401 on October 30. The pullback extended a longer downtrend that has kept the stock trading well below the $1.00 NYSE American minimum, keeping continued listing-compliance risk in focus.
XRPN fell -9.70% in early regular-session trading on Tuesday, sliding from Monday's $10.41 close to $9.40. The decline follows a November 9 SEC prospectus disclosing a committed equity facility with Cantor to sell up to 5.2 million new Class A shares at 97% of the volume-weighted average price, implying up to roughly 16.7% potential dilution.
NVDA dropped from Friday's close of $186.64 to $174.06 intraday, down -6.74%, during regular market hours. The slide followed CEO Jensen Huang's admission of an extramarital affair and the board's independent investigation, announced November 8, after reports he was targeted by a suspected Chinese intelligence operative.
CCAP climbed +7.03% during regular market hours, rising from a prior close of $9.24 to $9.89. The rally followed its Q3 2026 report: net investment income of $0.37/share beat the $0.35 consensus and revenue of $36.9M topped estimates, alongside a new $50M buyback authorization plus up to $25M in additional Sun Life purchases.
NVDA fell -2.10% to $216.66 during regular trading, down from a prior close of $221.30. Primary catalyst: hotter-than-expected September CPI data reignited Fed rate-hike fears, raising borrowing costs for AI infrastructure buildouts.